Patents by Inventor Yehuda Shoenfeld

Yehuda Shoenfeld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180280466
    Abstract: The present invention provides phosphorylcholine conjugates and pharmaceutical compositions comprising same for the prevention or treatment of autoimmune diseases. In particular, the conjugates of the present invention are effective in treating autoimmune diseases associated with pathological inflammation.
    Type: Application
    Filed: May 29, 2018
    Publication date: October 4, 2018
    Inventors: Yehuda SHOENFELD, Miriam BLANK
  • Patent number: 10046021
    Abstract: The present invention provides phosphorylcholine conjugates and pharmaceutical compositions comprising same for the prevention or treatment of autoimmune diseases. In particular, the conjugates of the present invention are effective in treating autoimmune diseases associated with pathological inflammation.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: August 14, 2018
    Assignee: TPCERA LTD.
    Inventors: Yehuda Shoenfeld, Miriam Blank
  • Patent number: 10040869
    Abstract: Specific peptides have been discovered that mimic an idiotype of an autoantibody. Such peptides may be formed into polymers. The peptides may be used in pharmaceutical compositions for the treatment of an autoimmune disease together with a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: May 26, 2013
    Date of Patent: August 7, 2018
    Assignee: OMRIX BIOPHARMACEUTICALS LTD.
    Inventors: Israel Nur, Yehuda Shoenfeld, Miri Blank
  • Patent number: 9987372
    Abstract: The present invention provides phosphorylcholine (PC)-conjugates and pharmaceutical compositions, particularly vaccines comprising same for the prevention or treatment of autoimmune diseases. In particular, the PC-conjugates of the present invention are effective in preventing or treating autoimmune diseases associated with pathological inflammation.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: June 5, 2018
    Assignee: TPCERA LTD.
    Inventors: Yehuda Shoenfeld, Miriam Blank
  • Patent number: 9975944
    Abstract: The present invention provides synthetic peptides, including peptides comprising a plurality of epitopes, each epitope being derived from a different protein, and peptides comprising a plurality of citrullinated residues. The present invention also related to use of said peptides for the treatment of autoimmune diseases and disorder.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: May 22, 2018
    Assignee: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Yehuda Shoenfeld, Howard Amital, Smadar Gertel
  • Publication number: 20160256516
    Abstract: The present invention provides phosphorylcholine conjugates and pharmaceutical compositions comprising same for the prevention or treatment of autoimmune diseases. In particular, the conjugates of the present invention are effective in treating autoimmune diseases associated with pathological inflammation.
    Type: Application
    Filed: December 1, 2015
    Publication date: September 8, 2016
    Inventors: Yehuda Shoenfeld, Miriam Blank
  • Publication number: 20160193350
    Abstract: The present invention provides phosphorylcholine (PC)-conjugates and pharmaceutical compositions, particularly vaccines comprising same for the prevention or treatment of autoimmune diseases. In particular, the PC-conjugates of the present invention are effective in preventing or treating autoimmune diseases associated with pathological inflammation.
    Type: Application
    Filed: February 5, 2014
    Publication date: July 7, 2016
    Inventors: Yehuda Shoenfeld, Miriam Blank
  • Publication number: 20160024183
    Abstract: The present invention provides synthetic peptides, including peptides comprising a plurality of epitopes, each epitope being derived from a different protein, and peptides comprising a plurality of citrullinated residues. The present invention also related to use of said peptides for the treatment of autoimmune diseases and disorder.
    Type: Application
    Filed: March 11, 2014
    Publication date: January 28, 2016
    Inventors: Yehuda Shoenfeld, Howard Amital, Smadar Gertel
  • Publication number: 20130244925
    Abstract: Specific peptides have been discovered that mimic an idiotype of an autoantibody. Such peptides may be formed into polymers. The peptides may be used in pharmaceutical compositions for the treatment of an autoimmune disease together with a pharmaceutically acceptable excipient.
    Type: Application
    Filed: May 26, 2013
    Publication date: September 19, 2013
    Applicant: Omrix Biopharmaceuticals Inc.
    Inventors: Israel NUR, Yehuda SHOENFELD, Miri BLANK
  • Patent number: 8450067
    Abstract: A method for identifying molecules which mimic an idiotype of an autoimmune disease-associated auto-antibody (autoantibodies). The method comprises the following steps: (a) purifying autoantibodies from sera of one or more patients afflicted with the autoimmune disease; (b) binding the autoantibodies to a solid phase to form an affinity matrix; (c) contacting pooled plasma or B cells comprising immunoglobulins with the affinity matrix followed by removal of unbound plasma components; (d) eluting bound immunoglobulins, being anti-Idiotypic antibodies (anti-Id) to autoantibodies, from the matrix; (e) providing a molecular library comprising a plurality of molecule members; and (e) contacting the anti-Id with the molecular library and isolating those bound molecules which are bound by the anti-Id, the bound molecules being molecules which mimic an idiotype of autoantibodies. Also disclosed are such molecules.
    Type: Grant
    Filed: May 22, 2003
    Date of Patent: May 28, 2013
    Assignee: Omrix Biopharmaceuticals Inc.
    Inventors: Israel Nur, Yehuda Shoenfeld, Miri Blank
  • Publication number: 20110064738
    Abstract: This invention relates to IVIG and fragments thereof and their use, specifically, provided herein are compositions and methods of inhibiting VEGF or VEGF receptor using polyclonal antibodies (pAb), or fragments thereof derived from human immunoglobulins.
    Type: Application
    Filed: June 24, 2010
    Publication date: March 17, 2011
    Inventors: Miri BLANK, Yehuda SHOENFELD
  • Publication number: 20100260760
    Abstract: This invention relates to IVIG and fragments thereof and their use, specifically, provided herein are compositions and methods of inhibiting VEGF or VEGF receptor using polyclonal antibodies (pAb), or fragments thereof derived from human immunoglobulins.
    Type: Application
    Filed: November 12, 2009
    Publication date: October 14, 2010
    Inventors: Miri Blank, Yehuda Shoenfeld
  • Publication number: 20090053217
    Abstract: This invention relates to IVIG and fragments thereof and their use, specifically, provided herein are compositions and methods of inhibiting VEGF or VEGF receptor using polyclonal antibodies (pAb), or fragments thereof derived from human immunoglobulins.
    Type: Application
    Filed: May 7, 2008
    Publication date: February 26, 2009
    Inventors: Miri Blank, Yehuda Shoenfeld
  • Publication number: 20080050390
    Abstract: This invention relates to cancer therapy and in particular to the administration of gamma globulins to inhibit both primary tumor and metastasis and augment treatment of primary cancerous tumors. In accordance with this invention, the treatment of various cancerous diseases is accomplished by administering a preparation containing intact gamma globulins or fragments thereof.
    Type: Application
    Filed: December 28, 2006
    Publication date: February 28, 2008
    Inventors: Yehuda Shoenfeld, Miri Blank
  • Publication number: 20070166313
    Abstract: This invention relates to cancer therapy and in particular to the administration of gamma globulins to inhibit both primary tumor and metastasis and augment treatment of primary cancerous tumors. In accordance with this invention, the treatment of various cancerous diseases is accomplished by administering a preparation containing intact gamma globulins or fragments thereof.
    Type: Application
    Filed: November 30, 2006
    Publication date: July 19, 2007
    Inventors: Yehuda Shoenfeld, Miri Blank
  • Patent number: 7053178
    Abstract: Synthetic peptides and derivatives thereof capable of inhibiting the biological activity of anti-beta-2-glycoprotein 1 (?2GPI) monoclonal antibodies (mAbs) in vitro, and of inhibiting induction of experimental anti-phospholipid syndrome (APS) in mice by anti-?2GPI mAbs, are provided for the diagnosis and treatment of anti-phospholipid syndrome in humans.
    Type: Grant
    Filed: November 29, 2004
    Date of Patent: May 30, 2006
    Assignee: Yeda Research Development Co., LTD
    Inventors: Miri Blank, Shmuel Cabilly, Yehuda Shoenfeld, Ephraim Katchalski-Katzir
  • Publication number: 20060078943
    Abstract: A method for identifying molecules which mimic an idiotype of an autoimmune disease-associated auto-antibody (autoantibodies). The method comprises the following steps: (a) purifying autoantibodies from sera of one or more patients afflicted with the autoimmune disease; (b) binding the autoantibodies to a solid phase to form an affinity matrix; (c) contacting pooled plasma or B cells comprising immunoglobulins with the affinity matrix followed by removal of unbound plasma components; (d) eluting bound immunoglobulins, being anti-Idiotypic antibodies (anti-Id) to autoantibodies, from the matrix; (e) providing a molecular library comprising a plurality of molecule members; and (e) contacting the anti-Id with the molecular library and isolating those bound molecules which are bound by the anti-Id, the bound molecules being molecules which mimic an idiotype of autoantibodies. Also disclosed are such molecules.
    Type: Application
    Filed: May 22, 2003
    Publication date: April 13, 2006
    Applicant: Omrix Biopharmaceuticals Inc.
    Inventors: Israel Nur, Yehuda Shoenfeld
  • Publication number: 20050197283
    Abstract: Methods and compositions employing beta2-glycoprotein-1 (?2GPI) or derivatives of ?2GPI effective in inducing mucosal tolerance to atheroma related antigens, thus inhibiting inflammatory processes contributing to atheromatous vascular disease and sequalae, are provided. Also provided are articles of manufacture comprising mucosal tolerance inducing amounts of beta2-glycoprotein-1 46 (?2GPI) or derivatives thereof.
    Type: Application
    Filed: April 15, 2005
    Publication date: September 8, 2005
    Applicant: Vascular Biogenics Ltd.
    Inventors: Dror Harats, Yehuda Shoenfeld, Niva Yacov, Jacob George
  • Publication number: 20050148499
    Abstract: A method for prevention and/or treatment of atherosclerosis in a subject, in need thereof is disclosed. The method is effected by orally administering to the subject an immunological oral tolerance-inducing composition which comprises an immunological oral tolerance-inducing amount of an active ingredient selected from the group consisting of beta2-glycoprotein-1 (?2GP-1) or a derivative of ?2GP-1.
    Type: Application
    Filed: November 17, 2004
    Publication date: July 7, 2005
    Inventors: Dror Harats, Yehuda Shoenfeld, Jacob George, Niva Yacov
  • Publication number: 20050107584
    Abstract: Synthetic peptides and derivatives thereof capable of inhibiting the biological activity of anti-beta-2-glycoprotein 1 (?2GPI) monoclonal antibodies (mAbs) in vitro, and of inhibiting induction of experimental anti-phospholipid syndrome (APS) in mice by anti-?2GPI mAbs, are provided for the diagnosis and treatment of anti-phospholipid syndrome in humans.
    Type: Application
    Filed: November 29, 2004
    Publication date: May 19, 2005
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.
    Inventors: Miri Blank, Shmuel Cabilly, Yehuda Shoenfeld, Ephraim Katchalski-Katzir